BOULDER, Colo., Aug. 12, 2019 /PRNewswire/ -- Encision Inc. ECIA, a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2020 first quarter that ended June 30, 2019.
The Company posted quarterly net revenue of $1.93 million for a quarterly net loss of $182 thousand, or $(0.02) per diluted share. These results compare to net revenue of $2.40 million for a quarterly net income of $18 thousand, or $0.00 per diluted share, in the year-ago quarter. Net revenue for the quarter ended June 30, 2018 included revenue from a higher number of capital monitor units sold, which delivers a higher sales price per unit than the sales price of other products that we sell. Gross margin on net revenue was 48% in the fiscal 2019 first quarter and 54% in the fiscal 2018 first quarter. Gross margin on net revenue was lower in the current quarter primarily as a result of significantly higher material costs, especially as a result of tariffs on our steel costs and higher labor and overhead costs, per unit of inventory, as a result of lower revenue and higher labor and overhead costs, per unit of inventory, as a result of lower revenue.
Last week, we entered into a loan and security agreement with Crestmark Bank. The loan is due on demand and has no financial covenants. Under the agreement, we were provided with a line of credit that is not to exceed the lesser of $1,000,000 or 85% of eligible accounts receivable. The interest rate is prime rate plus 1.5%, with a floor of 6.75%, plus a monthly maintenance fee of 0.4%, based on the average monthly loan balance. Interest is charged on a minimum loan balance of $500,000, a loan fee of 1% annually, and an exit fee of 3%, 2% and 1% during years one, two and three, respectively.
"For this fiscal year's first quarter, net revenue resulted in a 20% decline of revenue, said Greg Trudel, President and CEO of Encision Inc. "Because of the significantly higher material costs that were a result of the U.S. tariffs and the resulting loss, we have implemented a reduction of personnel and departmental spending in excess of $1 million annualized. We expect that the reductions will return us to profitability. While never satisfied with a loss of any magnitude, our confidence in our strategy to drive top line growth through new product introductions and channel expansion is unwavering."
Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended June 30, 2019 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.
CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com
Encision Inc. | ||||
Unaudited Condensed Statements of Operations | ||||
(in thousands, except per share information) | ||||
Three Months Ended | ||||
June 30, 2019 | June 30, 2018 | |||
Net revenue | $1,929 | $2,404 | ||
Cost of revenue | 996 | 1,103 | ||
Gross profit | 933 | 1,301 | ||
Operating expenses: | ||||
Sales and marketing | 530 | 776 | ||
General and administrative | 346 | 320 | ||
Research and development | 236 | 167 | ||
Total operating expenses | 1,112 | 1,263 | ||
Operating income (loss) | (179) | 38 | ||
Interest expense and other expense, net | (3) | (20) | ||
Income (loss) before provision for income taxes | (182) | 18 | ||
Provision for income taxes | –– | –– | ||
Net income (loss) | $ (182) | $ 18 | ||
Net income (loss) per share—basic and diluted | $(0.02) | $0.00 | ||
Weighted average number of shares— basic |
11,558 |
10,683 | ||
Weighted average number of shares— diluted |
11,558 |
10,705 | ||
Encision Inc. | ||||
Unaudited Condensed Balance Sheets | ||||
(in thousands) | ||||
June 30, 2019 | March 31, 2019 | |||
ASSETS | ||||
Cash and cash equivalents | $ 135 | $ 273 | ||
Restricted cash | –– | 25 | ||
Accounts receivable, net | 1,021 | 1,009 | ||
Inventories, net | 1,378 | 1,473 | ||
Prepaid expenses | 133 | 130 | ||
Total current assets | 2,667 | 2,910 | ||
Equipment, net | 234 | 250 | ||
Patents, net | 243 | 249 | ||
Right of use asset | 1,182 | –– | ||
Other assets | 19 | 19 | ||
Total assets | $ 4,345 | $ 3,428 | ||
LIABILITIES AND SHAREHOLDERS' EQUITY | ||||
Accounts payable | $ 438 | $ 579 | ||
Accrued compensation | 209 | 296 | ||
Other accrued liabilities | 138 | 126 | ||
Line of credit | 150 | –– | ||
Accrued lease liability | 159 | –– | ||
Total current liabilities | 1,094 | 1,001 | ||
Accrued lease liability | 1,074 | –– | ||
Deferred rent | –– | 75 | ||
Total liabilities | 2,168 | 1,076 | ||
Common stock and additional paid-in capital | 24,210 | 24,202 | ||
Accumulated (deficit) | (22,032) | (21,850) | ||
Total shareholders' equity | 2,177 | 2,352 | ||
Total liabilities and shareholders' equity | $ 4,345 | $ 3,428 | ||
Encision Inc. | |||||
Unaudited Condensed Statements of Cash Flows | |||||
(in thousands) | |||||
Three Months Ended | |||||
June 30, 2019 | June 30, 2018 | ||||
Operating activities: | |||||
Net income (loss) | $ (182) | $ 19 | |||
Adjustments to reconcile net income (loss) to cash generated by operating activities: | |||||
Depreciation and amortization | 43 | 48 | |||
Share-based compensation expense | 8 | 12 | |||
(Recovery from) provision for doubtful accounts, net | (6) | (3) | |||
(Recovery from) inventory obsolescence, net | (10) | –– | |||
Changes in operating assets and liabilities: | |||||
Right of use asset | 49 | –– | |||
Accounts receivable | (6) | (285) | |||
Inventories | 105 | 201 | |||
Prepaid expenses and other assets | (3) | (44) | |||
Accounts payable | (141) | (17) | |||
Accrued compensation and other accrued liabilities | (148) | (73) | |||
Net cash (used in) operating activities | (291) | (142) | |||
Investing activities: | |||||
Acquisition of property and equipment | (21) | (5) | |||
Patent costs | (1) | (1) | |||
Net cash (used in) investing activities | (22) | (6) | |||
Financing activities: | |||||
Borrowings from credit facility, net change | 150 | 87 | |||
Net cash generated by financing activities | 150 | 87 | |||
Net (decrease) in cash, cash equivalents and restricted cash | (163) | (61) | |||
Cash, cash equivalents and restricted cash, beginning of period | 298 | 139 | |||
Cash, cash equivalents and restricted cash, end of period | $ 135 | $ 78 | |||
View original content:http://www.prnewswire.com/news-releases/encision-reports-first-quarter-fiscal-year-2020-results-300899539.html
SOURCE Encision Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
